Skip to main content

Table 4 Predictive value of GA for the risk of MACCE

From: Prognostic implication of serum glycated albumin for patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention

  As nominal variatea As continuous variateb
HR (95% CI) P value HR (95% CI) P value
Unadjusted 1.826 (1.536–2.171) < 0.001 1.072 (1.054–1.091) < 0.001
Model 1 1.639 (1.374–1.956) < 0.001 1.065 (1.046–1.083) < 0.001
Model 2 1.510 (1.226–1.858) < 0.001 1.063 (1.039–1.088) < 0.001
Model 3 1.610 (1.304–1.987) < 0.001 1.063 (1.038–1.089) < 0.001
Model 4 1.602 (1.297–1.979) < 0.001 1.062 (1.036–1.088) < 0.001
Model 5 1.527 (1.236–1.886) < 0.001 1.053 (1.027–1.079) < 0.001
  1. Model 1: adjusted for age, gender, BMI
  2. Model 2: adjusted for variates in Model 1 and smoking history, hypertension, T2DM, anemia, previous MI, previous PCI, previous stroke
  3. Model 3: adjusted for variates in Model 2 and TG, TC, creatinine, hs-CRP, HDL-C, LVEF
  4. Model 4: adjusted for variates in Model 3 and OHA at discharge, insulin at discharge
  5. Model 5: adjusted for variates in Model 4 and left main artery lesion, multi-vessel lesion, SYNTAX score, complete revascularization, number of DES
  6. aThe HR was evaluated regarding the lower median of GA as reference
  7. bThe HR was evaluated by per 1-unit increase of GA
  8. HR hazard ratio, CI confidence interval